Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc Interim Data Update Transcript

Nov 06, 2023 / 01:30PM GMT
Release Date Price: $15.79 (+3.00%)
Operator

Good day, and thank you for standing by. Welcome to REGENXBIO's data update from Phase II ALTITUDE trial of ABBV-RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery from AAO 2023.Ã (Operator Instructions) After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions)

Please be advised today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Ken Mills, Chief Executive Officer. Please go ahead.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Welcome, everyone, to our American Academy of Ophthalmology or AAO event update. I'm Ken Mills, CEO of REGENXBIO, and I'm pleased to introduce our agenda and make some opening remarks. This event is designed to review and discuss the new interim data from our ALTITUDE clinical trial ofà ABBV-RGX-314,à henceforthà referred to as 314 for diabetic retinopathy or DR using one-time in-office suprachoroidal delivery. The slides for this presentation are available on the webcast and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot